{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:57:19Z","timestamp":1784872639432,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2701202"],"award-info":[{"award-number":["2021YFC2701202"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20368"],"award-info":[{"award-number":["U20A20368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijid.2024.107363","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:01:28Z","timestamp":1734609688000},"page":"107363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16\/18 infections and CIN2+ in women: a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"151","author":[{"given":"Haiyue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuFei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.107363_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijid.2024.107363_bib0002","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2021.08.029","article-title":"Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer","volume":"163","author":"Wang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijid.2024.107363_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070115","article-title":"Human papillomavirus vaccination and cervical cancer risk","volume":"379","author":"Rahangdale","year":"2022","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ijid.2024.107363_bib0005","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2024.107363_bib0006","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2024.2673","article-title":"Population-based incidence of cervical intraepithelial neoplasia across 14 years of HPV vaccination","volume":"10","author":"Adcock","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijid.2024.107363_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0008","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/jiaa561","article-title":"Efficacy of AS04-adjuvanted vaccine against human papillomavirus (HPV) types 16 and 18 in clearing incident HPV infections: pooled analysis of data from the costa Rica vaccine trial and the Patricia study","volume":"223","author":"Tota","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2024.107363_bib0009","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.34882","article-title":"Efficacy and immunogenicity of AS04-HPV-16\/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide","volume":"154","author":"Wen","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijid.2024.107363_bib0010","unstructured":"Immunization coverage. 2024 [cited 2024 15 July]; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage."},{"key":"10.1016\/j.ijid.2024.107363_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1386167","article-title":"Cervical cancer prevention by vaccination: review","volume":"14","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijid.2024.107363_bib0012","doi-asserted-by":"crossref","first-page":"e29480","DOI":"10.1002\/jmv.29480","article-title":"Eliminating cervical cancer in China: opportunities come and challenges remain","volume":"96","author":"Ou-Yang","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijid.2024.107363_bib0013","doi-asserted-by":"crossref","first-page":"e6862","DOI":"10.1002\/cam4.6862","article-title":"A comprehensive narrative review of challenges and facilitators in the implementation of various HPV vaccination program worldwide","volume":"13","author":"Aggarwal","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijid.2024.107363_bib0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ygyno.2013.05.033","article-title":"HPV vaccine cross-protection: highlights on additional clinical benefit","volume":"130","author":"De Vincenzo","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijid.2024.107363_bib0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/erv.09.123","article-title":"Currently approved prophylactic HPV vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2024.107363_bib0016","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1908059","article-title":"Review of long-term immunogenicity following HPV vaccination: gaps in current knowledge","volume":"18","author":"Hoes","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2024.107363_bib0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/DDDT.S91018","article-title":"Spotlight on the 9-valent HPV vaccine","volume":"11","author":"Lopalco","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.ijid.2024.107363_bib0018","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0019","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/M15-0930","article-title":"The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses","volume":"162","author":"Cornell","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2024.107363_bib0020","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0021","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0022","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijid.2024.107363_bib0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/jebm.12264","article-title":"Software and package applicating for network meta-analysis: A usage-based comparative study","volume":"11","author":"Xu","year":"2018","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.ijid.2024.107363_bib0024","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.ijid.2024.107363_bib0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2022.101646","article-title":"Effects of cognitive behavioral therapy for insomnia (CBT-I) on quality of life: A systematic review and meta-analysis","volume":"64","author":"Alimoradi","year":"2022","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.ijid.2024.107363_bib0027","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/14760584.2023.2287135","article-title":"Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis","volume":"22","author":"Lin","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2024.107363_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CM9.0000000000002814","article-title":"Fixed-effect and random-effects models in meta-analysis","volume":"137","author":"Zhai","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ijid.2024.107363_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/v9100267","article-title":"Natural History of HPV Infection across the Lifespan: Role of Viral Latency","volume":"9","author":"Gravitt","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2024.107363_bib0030","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ygyno.2008.02.002","article-title":"Age considerations when vaccinating against HPV","volume":"109","author":"Wright","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijid.2024.107363_bib0031","doi-asserted-by":"crossref","first-page":"g7584","DOI":"10.1136\/bmj.g7584","article-title":"Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model","volume":"350","author":"Jit","year":"2015","journal-title":"Bmj"},{"key":"10.1016\/j.ijid.2024.107363_bib0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijid.2024.107363_bib0033","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/infdis\/jiaa007","article-title":"Persisting Antibody Response 9 Years After Bivalent Human Papillomavirus (HPV) Vaccination in a Cohort of Dutch Women: Immune Response and the Relation to Genital HPV Infections","volume":"221","author":"Hoes","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2024.107363_bib0034","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2024.107363_bib0035","doi-asserted-by":"crossref","first-page":"e61825","DOI":"10.1371\/journal.pone.0061825","article-title":"A randomized, observer-blinded immunogenicity trial of Cervarix(\u00ae) and Gardasil(\u00ae) Human Papillomavirus vaccines in 12-15 year old girls","volume":"8","author":"Draper","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2024.107363_bib0036","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.vaccine.2014.07.014","article-title":"Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes","volume":"32","author":"Barzon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2024.107363_bib0037","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/OGX.0b013e31819f992e","article-title":"The HPV vaccines\u2013which to prefer?","volume":"64","author":"Bornstein","year":"2009","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ijid.2024.107363_bib0038","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijid.2024.107363_bib0039","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4161\/hv.22994","article-title":"A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France","volume":"9","author":"Bresse","year":"2013","journal-title":"Hum Vaccin Immunother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224004387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224004387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:26:29Z","timestamp":1778592389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224004387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"alternative-id":["S1201971224004387"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107363","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16\/18 infections and CIN2+ in women: a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107363"}}